Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis
Key facts
- Who runs it
- Ruijin Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Treatments tested
- Inebilizumab
- Record updated
- 7 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- A signed and dated informed consent form
- A commitment to adhere to the study protocol and to cooperate throughout the entire study
- Aged 18 years or over, regardless of gender
- Diagnosed with Type I AIP
- Indications for treatment: (1) For symptomatic participants, evidence of pancreatic involvement (e.g. obstructive jaundice, abdominal pain, lower back pain) and extra-pancreatic organ involvement (e.g. jaundice caused by bile duct stricture); (2) Asymptomatic participants with subclinical AIP that may progress to severe, irreversible damage to vital organs (e.g. persistent pancreatic mass, abnormal liver function accompanied by proximal IgG4-related sclerosing cholangitis)
- Be able to adhere to and cooperate with study interventions, such as taking oral medication
- If a woman of childbearing potential, she must have used contraception for at least one month prior to screening and undertake to use contraception throughout the study period and for a specified period following the study's conclusion
Who cannot take part
- Concurrent malignant tumours
- Concurrent uncontrolled underlying conditions, such as severe heart failure or respiratory failure
- History of mental illness
- Allergy to the study intervention
- Infectious diseases such as active hepatitis or tuberculosis
- Participants meeting any of the following criteria will be excluded from this study:
- Women who are trying to conceive, are pregnant or are breastfeeding
- Those who are unable or refuse to sign the informed consent form
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Type 1 AIP
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Autoimmune pancreatitis (AIP) is an immune-related inflammatory disease of the pancreas. Relapse can occur after treatment, and long-term treatment with glucocorticoids and conventional immunosuppressants can cause significant side effects.
Read full original descriptionShow less
This multicenter, single-arm, open-label study aims to evaluate the efficacy and safety of inebilizumab in patients with AIP. Inebilizumab targets CD19 and reduces B cells, including plasmablasts.
The study plans to enroll 50 patients with confirmed AIP, including both newly diagnosed patients and patients with relapsing disease. All eligible participants will receive inebilizumab and follow a standardized glucocorticoid dose-reduction regimen.
The primary objective is to assess whether inebilizumab can reduce the relapse rate within 32 weeks. Secondary objectives are to assess its effects on glucocorticoid use, serum IgG4 levels, B-cell counts, and other immune cells.
Peripheral blood samples and lymph node samples will be collected for exploratory mechanistic analyses to characterize circulating and tissue immune-cell populations and blood-based biomarkers during treatment and follow-up.
The group in the trial
- Inebilizumab TreatmentTreatment being tested
All patients with type 1 AIP received a standardised glucocorticoid tapering regimen: 30 mg/day for one month, followed by a reduction of one tablet every two weeks to 20 mg/day. Treatment with Inelizumab was initiated as follows: Day 1: intravenous infusion of Inelizumab 300 mg; Day 15: intravenous infusion of Inelizumab 300 mg. Maintenance phase: Thereafter, one infusion of 300 mg every 24 weeks (6 months) until the end of the study.Peripheral blood and lymph node sampling is planned at specified study visits and at disease relapse for exploratory mechanistic analyses, as detailed in the study description.
Treatment: Inebilizumab
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Inebilizumab for the Treatment of Patients With Relapsing Type 1 Autoimmune Pancreatitis: A Multicenter, Single-Arm, Open-Label Study
- Criteria questions
- Built from NCT07862075, who can take part
- Record updated
- 7 October 2026